This document provides a review of evidence on three topics of interest (effectiveness of partial vaccination, immunogenicity and effectiveness of vaccination for previously infected individuals and safety and immunogenicity of heterologous schedules) to inform ongoing decision-making in relation to national vaccination policies and strategies in the European Union and European Economic Area (EU/EEA) countries.
This study provides insights for national public health authorities into the factors behind the spread of vaccine misinformation online and the options and capacities needed for responding to it.
The aim of this threat assessment brief is to assess potential public health implications of the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern for the EU/EEA.
This report presents evidence on the impact of COVID-19 on migrant populations in EU/EEA countries; risk factors for increased COVID-19 exposure in migrant populations; and considerations for ensuring equitable access to the COVID-19 vaccine for migrant populations.
The purpose of this document is to address the safety of donors and products involving Substances of Human Origin (SoHO) and the potential risk of thrombosis with thrombocytopenia adverse events following COVID-19 vaccination of a donor.
This technical report provides a set of interim public health considerations to support EU/EEA public health authorities taking decisions on the administration of COVID-19 vaccines to adolescents (12- to 18-year-olds).
This technical report provides a summary of the evidence available at the time of the publication and what will be required in the future to support EU/EEA countries taking decisions on administration of the second dose, following a first dose of Vaxzevria. Since new evidence is being generated continuously and safety monitored on an ongoing basis, it is essential for readers to consider the latest available information.